GVK Biosciences opens new Clinical Pharmacology Unit in Ahmedabad
New facility commissioned to meet increasing business demand
GVK Biosciences (GVK BIO) announced that it has commissioned its new clinical pharmacology unit (CPU) in Ahmedabad, India. The Ahmedabad CPU adds 110 beds to GVK BIO’s existing capacity of 144 beds. The new CPU will conduct a variety of studies in healthy volunteers.
Ahmedabad was the most preferred and logical destination for expansion considering the volunteer pool accessibility and proximity to about 10 CROs and leading Pharma companies. With 3 clinical wards and 110 beds, the Unit is state-of-the-art and designed to suit all regulatory requirements. It also has special housing facilities for female volunteers. Key features of this Unit include access to special population like young women, post-menopausal women, diseased population and access to about 12,000 healthy volunteers.
“The opening of the new GVK BIO Clinical Pharmacology unit reflects our commitment to offer faster recruitment solutions to our customers. The facility has been audited by the DCGI and we have initiated our first study at the Ahmedabad facility”, said Manni Kantipudi, President, GVK Biosciences.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.